Humuline 30/70 Cartridge (Insulin Human (Rdna))

Humuline 30/70 Cartridge is a prescription insulin product that contains human insulin produced by recombinant DNA technology (Insulin Human). It provides a premixed formulation of 30% soluble (regular) insulin and 70% isophane (NPH) insulin, supplied in a cartridge compatible with insulin pens for subcutaneous injection. The product is marketed in the European Union and is used to manage blood glucose in diabetes patients as part of a treatment plan.

Humuline 30/70 Cartridge is indicated for the control of hyperglycemia in adults with diabetes.

- Type 1 diabetes mellitus requiring basal‑bolus insulin therapy. - Type 2 diabetes mellitus when oral agents no longer provide adequate glycemic control. - Adjunct to diet and exercise in patients needing both rapid‑acting and intermediate‑acting insulin. - Use during pregnancy only if benefits outweigh risks and under medical supervision.

Like all insulin preparations, Humuline 30/70 may cause adverse reactions, ranging from mild to severe.

Common: - Hypoglycemia, presenting as shakiness, sweating, confusion, or dizziness, especially if meals are missed or activity is increased. - Local injection‑site reactions such as redness, swelling, itching or mild bruising that usually resolve within days. - Gradual weight gain associated with improved glycemic control and increased caloric storage.

Serious: - Severe hypoglycemia causing loss of consciousness, seizures, or need for assistance from another person. - Anaphylactic reaction characterized by difficulty breathing, throat swelling, hives, and rapid onset requiring emergency care. - Fluid retention leading to peripheral edema or worsening of pre‑existing heart failure.

Before using Humuline 30/70, certain precautions should be considered to ensure safe and effective therapy.

- Monitor blood glucose regularly to adjust dose and avoid hypoglycemia. - Adjust insulin dose during illness, surgery, or changes in physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Review pregnancy and lactation status; insulin may be required but risks and benefits should be evaluated. - Be aware of potential hypoglycemia unawareness, especially in long‑standing diabetes. - Avoid mixing Humuline 30/70 with other insulins or diluents unless specifically instructed.

Humuline 30/70 can interact with several medicines, affecting blood glucose levels or insulin action.

Avoid: - Beta‑blockers that may mask hypoglycemia symptoms. - MAO‑inhibitors that can potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics that may raise blood glucose.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) increasing hypoglycemia risk. - Corticosteroids that raise glucose and may require higher insulin doses. - Alcohol, especially in excess, which can cause unpredictable glucose fluctuations.